Gentamycin sulfate Raw Materials Powder 1405-41-0

CAS:1405-41-0

MF: C60H127N15O26S

MW:1506.8

EINECS:215-778-9

Specification: 99% min gentamycin sulfate Powder

Sample: gentamycin sulfate Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: colorless to light yellow

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Gentamycin sulfate Powder Usage and Synthesis.

Gentamicin Sulfate is a glycoside bactericidal antibiotic linked by aminosugar and ligand, it is the sulfate of Gentamicin, and its antibacterial spectrum is similar to that of Kanamycin.

It is mainly used for systemic or local infections caused by gram-negative bacteria such as Escherichia coli, dysentery bacillus, Klebsiella pneumoniae, Proteus mirabilis and Pseudomonas aeruginosa. Ophthalmology is used for conjunctivitis and keratitis.

Oral can be used for intestinal infections or colon surgery preparation; can also be used in combination with metronidazole or clindamycin to reduce the infection rate of colon surgery. 

Gentamicin Sulfate has good antibacterial effect on various Gram-negative and Gram-positive bacteria, and has good antibacterial effect on various Enterobacteriaceae, such as Escherichia coli, Klebsiella spp, Aspergillus spp, Salmonella spp, Shigella spp, Enterobacter spp, Serratia spp, and Pseudomonas aeruginosa.

Neisseria spp. and Haemophilus influenzae are moderately sensitive to this product. It also has a certain effect on Brucella spp., Plasmodium spp. and Campylobacter fetus.

It has good antibacterial effect on about 80% of methicillin-sensitive strains of staphylococci (including Staphylococcus aureus and coagulase-negative staphylococci), but the methicillin-resistant strains are mostly resistant to Gentamicin Sulfate.

The effect on Streptococcus spp. and Streptococcus pneumoniae is poor, and Enterococcus spp. are mostly resistant to the product. In recent years, there has been a significant increase in gentamicin-resistant strains of Gram-negative bacilli. When this product is used in combination with β-lactams, most of the synergistic antibacterial effect can be obtained.

Uses and functions of gentamycin sulfate.

Gentamicin blocks the transfer of peptidyl-tRNA from the acceptor site to the donor site by binding to the 30S ribosomal subunit and causing a codon misreading.

The bactericidal effect of gentamicin against Pseudomonas aeruginosa relies on binding to the outer membrane portion of the cell membrane, displacing the cations that would otherwise be present, destabilising the membrane, and forming cavities on the cell surface. Antibacterial spectrum:Gram-negative bacteria, Staphylococcus and other Gram-positive bacteria.

Clinically used for sepsis, respiratory tract infections, biliary tract infections, purulent peritonitis, intracranial infections, urinary tract infections and bacillary dysentery caused by Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, dysentery bacillus, Klebsiella, Proteus mirabilis and other sensitive bacteria.

For the treatment of septicaemia, urinary tract infections, staphylococcal infections, endocarditis and other diseases.

Pharmacological Effect of gentamycin sulfate.

Gentamicin sulphate is an aminoglycoside drug that acts on the ribosome in bacteria, inhibiting bacterial protein synthesis and disrupting the integrity of the bacterial cell membrane to exert bactericidal action.

Gentamicin sulphate can first pass through extracellular membrane pore proteins by passive diffusion, then enter the cell via the cell membrane via the transporter system and irreversibly bind to the 30s subunit of isolated ribosomes, leading to the disruption of the A-site, which in turn:

(1) Preventing the correct localisation of aminoacyl tRNA at the A-site, especially hindering the binding of methionyl tRNA, thereby interfering with the assembly of functional ribosomes and inhibiting the formation of the 70s initiation complex.

(2) Induces a mismatch between tRNA and mRNA codon triplets, causing misreading of the genetic code of the 30s subunit of the intact ribosome, resulting in the insertion of incorrect amino acids into the protein structure, leading to abnormal, non-functional protein synthesis.

(3) Hinders the binding of the termination factor to the A site, preventing the release of the synthesised peptide chain and preventing the dissociation of the 70s intact ribosome.

(4) Hinders the process of polyribosome depolymerisation and assembly, resulting in ribosome depletion in bacteria.

Drug interactions of  Bulk gentamycin sulfate Powder.

(1) Combination with other aminoglycosides or sequential consecutive local or systemic application may increase their production of ototoxicity, nephrotoxicity and neuromuscular blocking effects.

(2) Combined with neuromuscular blocking drugs, it may aggravate the neuromuscular blocking effect, resulting in muscle weakness, respiratory depression and other symptoms.

(3)Combination with colistin, cisplatin, etanercept, furosemide, vancomycin, desmethyl vancomycin, etc., or successive consecutive local or systemic applications, may increase ototoxicity and nephrotoxicity.

(4) Gentamicin sulphate may increase nephrotoxicity when used in combination with cefotiophene and cefazolin topically or systemically.

(5)Combination with polymyxin-like injections or successive local or systemic applications may increase nephrotoxicity and neuromuscular blockade.

(6) Gentamicin sulphate should not be combined with other nephrotoxic and ototoxic drugs or successive consecutive applications, so as not to aggravate nephrotoxicity or ototoxicity.